Strategies and testing methods for identifying mutagenic risks.
The evolution of testing strategies and methods for identification of mutagenic agents is discussed, beginning with the concern over potential health and population effects of chemical mutagens in the late 1940s that led to the development of regulatory guidelines for mutagenicity testing in the 1970s and 1980s. Efforts to achieve international harmonization of mutagenicity testing guidelines are summarized, and current issues and needs in the field are discussed, including the need for quantitative methods of mutagenic risk assessment, dose-response thresholds, indirect mechanisms of mutagenicity, and the predictivity of mutagenicity assays for carcinogenicity in vivo. Speculation is offered about the future of mutagenicity testing, including possible near-term changes in standard test batteries and the longer-term roles of expression profiling of damage-response genes, in vivo mutagenicity testing methods, and models that better account for differences in metabolism between humans and laboratory model systems.
MacGregor
J T
JT
FDA Center for Drug Evaluation and Research, 5600 Fishers Lane, Rockville, MD 20857, USA. macgregorj@cder.fda.gov
Casciano
D
D
Müller
L
L
D015197:Carcinogenicity Tests / Q000592:standards*; D002273:Carcinogens; D006801:Humans; D009152:Mutagenicity Tests / Q000592:standards*; D009153:Mutagens; D018570:Risk Assessment / Q000379:methods*
D002273:Carcinogens; D009153:Mutagens